A Stark Divide: Analyst Conviction Meets Market Reality for Redcare Pharmacy

Redcare Pharmacy shares hit 52-week low despite analyst 'Buy' ratings. Downturn follows cut to 2026 profit margin target and slower growth in key OTC segment.

A significant gulf has emerged between professional analysts and the trading floor regarding Redcare Pharmacy. While nine major research firms maintain a "Buy" rating with an average price target just under €95, the market tells a different story. The company's shares are currently trading at a 52-week low, having shed approximately 75% of their value over the past twelve months. Such a wide divergence between institutional expectations and actual price performance is a rare sight.

Profitability Guidance Revision Sparks Sell-Off

The current downturn traces back to early March 2026. On March 4, Redcare Pharmacy announced a substantial revision to its medium-term EBITDA margin target, lowering it from "over 8%" to "over 5%." Although the company's long-term ambition to reach an 8% margin remains intact, investors responded to this near-term correction with sustained selling pressure.

Compounding the issue was a disappointing revenue forecast for 2026. Management now anticipates growth of 13% to 15%, falling short of the roughly 17.5% analysts had previously modeled. A particular concern is the performance of the higher-margin non-prescription (Non-Rx) business, which is projected to grow by only 8% to 10%. This segment's slowdown has already exerted pressure, reducing the gross margin to 21.3% in 2025.

Robust Growth Masks Underlying Structural Challenges

Redcare's top-line growth figures remain strong. In 2025, the company generated total revenue of €2.94 billion, representing a 24% year-over-year increase. Its prescription (Rx) business surpassed the €1 billion mark for the first time, with sales in Germany alone nearly doubling to €503 million.

The core problem is structural. The company is experiencing vigorous expansion in the lower-margin prescription sector while seeing a deceleration in the more profitable over-the-counter (OTC) segment. For investors who had bet on a rapid expansion of profitability, this combination presents an unwelcome dynamic.

Technical Indicators Signal Extreme Oversold Conditions

From a technical perspective, the stock appears deeply oversold, with a Relative Strength Index (RSI) reading of 17. Such levels can sometimes trigger short-term rebounds. However, both short-term and long-term moving averages remain positioned far above the current share price, underscoring the persistent downward trend.

Analysts at Berenberg and Deutsche Bank reaffirmed their Buy recommendations in early March. The upcoming release of first-quarter 2026 results, expected in the coming weeks, now represents a critical test. Whether these figures can provide enough positive momentum to restore investor confidence will be the next decisive moment for Redcare Pharmacy shares.